Clinical Science - Publications - Pioneering Science - Elpiscience

Publications

2026 Human Vaccines & Immunotherapeutics

LILRB2 inhibition by blocking antibody ES009 reprograms immunosuppressive myeloid cells and enhances T-cell-mediated tumor immunity

2026 AAI

ES302, A Novel TL1A/IL-23p19 Bi-specific Antibody Demonstrates Robust Efficacy and Developability for Inflammatory Bowel Disease

2026 AACR

First-in-human study of ES014, a bispecific antibody targeting CD39 and TGF-β as monotherapy in patients with advanced solid tumors

2025 ESMO Asia

First-in-human study of ES014, a bispecific antibody targeting CD39 and TGF-β as monotherapy in patients with advanced solid tumors

ES038, a novel NKCE molecule targeting LILRB4 in AML via dual engagement of NKG2A and NKG2C

A first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the LILRB2 inhibitor ES009 in patients with advanced solid tumors

Novel bispecific macrophage engager (BiME) antibodies activate T cells and induce durable immune memory to suppress tumor growth

2024 Antibody Therapeutics

A pan-allelic human SIRPα blocking antibody, ES004-B5 promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response

A novel bispecific antibody macrophage engager (BiME) designed for the treatment of solid tumors

An NKG2A antibody-IL-2 mutant fusion protein for cancer immunotherapy

A novel bi-functional antibody fusion protein for the inhibition of TGFβ pathway in cancer immunotherapy via selective delivery of TGFβ “trap” to CD39-expressing cells

Selective delivery of TGFβ “trap” to CD39-expressing immune and stroma cells in TME reshapes tumor microenvironment and rejuvenates antitumor immunity

ES008-a, a high affinity LILRB1-specific blocking antibody activates multiple immune cells to fight cancers

ES015-2, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response

Preclinical characterization of a novel anti-CD39/TGFβ-trap bispecific antibody that aims to modulate tumor microenvironment

Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity

ES009, a LILRB2 specific blocking antibody, potently reprograms myeloid cells into pro-inflammation phenotypes and potentiates T cell activation

ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions of LAG3 with multiple ligands and enhances anti-tumor activity of T cells in preclinical models

Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity

SIGLEC15 induces monocyte apoptosis and an SIGLEC15 antibody ES012 reverses myeloid cells driven immunosuppression

Creating an Immune-favorable Tumor Microenvironment by A Novel Anti-CD39/TGFβ-Trap Bispecific Antibody

A Novel Bispecific Macrophage Engager Antibody (BiME) Designed for Cancer Therapy

Anti-SIRPα Antibodies Stimulate Macrophage Phagocytosis to Cancer Cells in Both CD47- dependent and CD47-independent Manners

The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells